The United States Supreme Court yesterday made a landmark antitrust decision that should hopefully have the effect of increasing generic competition with brand name drugs, lowering pharmaceutical costs for consumers and their insurers. In Federal Trade Commission v. Actavis, Inc., the Court recognized the potential anticompetitive effects of “reverse payment” settlements that have grown increasingly pervasive in patent litigation. To read the decision, click here. To read more about Wexler Wallace’s antitrust cases, please click here.
Supreme Court Makes Landmark Antitrust Ruling
June 18, 2013by Amy Sayre, Paralegal